PriceTargets.com logo

Zevra Therapeutics - ZVRA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.00
  • Forecasted Upside: 118.78%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$5.49 As of 03/30/2023 01:00 AM ET
▼ -0.08 (-1.44%)

This chart shows the closing price for ZVRA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Zevra Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ZVRA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZVRA

Analyst Price Target is $12.00
▲ +118.78% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Zevra Therapeutics in the last 3 months. The average price target is $12.00, with a high forecast of $12.00 and a low forecast of $12.00. The average price target represents a 118.78% upside from the last price of $5.49.

This chart shows the closing price for ZVRA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Zevra Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/6/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/4/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/4/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/1/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/30/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/30/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/17/2023Maxim GroupInitiated CoverageBuy$12.00Low
(Data available from 3/30/2018 forward)

News Sentiment Rating

0.15 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/1/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/29/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/28/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/30/2023

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Zevra Therapeutics logo
Zevra Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.
Read More

Today's Range

Now: $5.49
Low: $5.40
High: $5.71

50 Day Range

MA: N/A

52 Week Range

Now: $5.49
Low: $4.00
High: $6.92

Volume

278,408 shs

Average Volume

231,788 shs

Market Capitalization

$189.45 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.15

Frequently Asked Questions

What sell-side analysts currently cover shares of Zevra Therapeutics?

The following Wall Street research analysts have issued stock ratings on Zevra Therapeutics in the last year: Maxim Group.
View the latest analyst ratings for ZVRA.

What is the current price target for Zevra Therapeutics?

1 Wall Street analysts have set twelve-month price targets for Zevra Therapeutics in the last year. Their average twelve-month price target is $12.00, suggesting a possible upside of 118.8%. Maxim Group has the highest price target set, predicting ZVRA will reach $12.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $12.00 for Zevra Therapeutics in the next year.
View the latest price targets for ZVRA.

What is the current consensus analyst rating for Zevra Therapeutics?

Zevra Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ZVRA will outperform the market and that investors should add to their positions of Zevra Therapeutics.
View the latest ratings for ZVRA.

What other companies compete with Zevra Therapeutics?

Other companies that are similar to Zevra Therapeutics include Annexon, ALX Oncology, UroGen Pharma, AC Immune and Ovid Therapeutics. Learn More about companies similar to Zevra Therapeutics.

How do I contact Zevra Therapeutics' investor relations team?

Zevra Therapeutics' physical mailing address is 1180 Celebration Boulevard Suite 103, Celebration FL, 34747. The company's listed phone number is (321) 939-3416 and its investor relations email address is [email protected] The official website for Zevra Therapeutics is www.kempharm.com. Learn More about contacing Zevra Therapeutics investor relations.